Overview: MUC4 Immunohistochemistry TestIntroduction: The MUC4 Immunohistochemistry Test detects MUC4 protein to diagnose pancreatic or lung cancer, causing pain or cough. Following 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected pancreatic or lung malignancies.
Other Names: MUC4 IHC Assay, Pancreatic/Lung Cancer IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: MUC4 testing began in the 2000s with pancreatic and lung cancer research. Immunohistochemistry-based methods improved diagnostic precision.
Purpose: Detects MUC4 to diagnose pancreatic or lung cancer, guides treatment, and evaluates patients with pain or cough.
Test Parameters: 1. MUC4 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of abdominal pain, cough, or weight loss.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document abdominal pain, cough, weight loss, or family history of pancreatic or lung cancer. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect MUC4 in pancreatic or lung tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for pancreatic or lung cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive MUC4 staining suggests pancreatic or lung cancer, guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: CA 19-9, CK7 IHC, or PET-CT to confirm pancreatic or lung cancer diagnosis.
Test Limitations: Not specific to one cancer type; other tumors may express MUC4. Clinical correlation is needed.
References: NCCN Pancreatic Cancer Guidelines, 2023; American Journal of Surgical Pathology, Basturk O, 2022.
